Quanterix Marks One-Year Anniversary of IPO with Key Milestones Accelerating Healthcare Disruption Ahead of Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Company celebrates remarkable growth in 2018 fueled by new product launches, acceleration of ground-breaking publications and rapid adoption of digital biomarkers in neurology and oncology research
Since going public and listing
on the Nasdaq on
“The past year has been rewarding for us as a company and we are showing
no signs of slowing down,” said
Significant 2018 Achievements:
Launched the SR-X
Ultra-Sensitive Biomarker Detection System™ in
January 2018, less than one month after public offering, offering researchers lower-cost and smaller footprint access to Simoa technology.
- Acquired Aushon BioSystems and successfully integrated the two companies. The acquisition included a CLIA certified laboratory, expanding services and accelerating entry into pharmaceutical drug trial services, as well as access to novel immunoassay technology to which Simoa sensitivity algorithms are being applied to deliver next-generation Simoa capabilities.
- Initiated a collaboration with DestiNA Genomics in an effort to transform microRNA biomarker detection, bringing together high-specificity and ultra-sensitivity for the first time.
- Gained unrestricted rights back for its Simoa technology in IVD markets with the termination of a license agreement with bioMérieux.
- Increased new publications dramatically by 145, bringing the total to 360 (nearly 50% growth).
- Rapid adoption of proprietary Neurofilament light chain (NfL) assay, a biomarker previously mainly measured only in cerebral spinal fluid, but by using Simoa, researchers have shown it can be measured in blood and correlated to central spinal fluid (CSF) results. This advance has enabled many novel applications critical for advancing the early detection, treatment and prevention of neurological diseases, including multiple sclerosis (MS); Parkinson’s disease; Alzheimer’s disease; brain cancer; and traumatic brain injuries (TBIs).
Invited by the
FDAto present recent progress and potential future strategy for NfL to senior agency officials.
Announced partnerships with
Abbott Labsfor blood screening and Oncogenesisfor a cervical cancer screening test.
- Launched a test bed/early access program for a new next-generation 10-plex Simoa planar array for oncology research and drug development with a benchtop imager called the SP-X™ Imaging and Analysis System.
Increased headcount from 149 to 181 (>20%) and expanded the leadership
team with the hiring of
Jackson Streeter, M.D., to lead corporate development and strategy, formerly Chief Medical Officer and Chief Executive Officer of Banyan Biomarkers and Dawn Mattoon, Ph.D., to lead strategic market and assay technology, formerly Head of Product Development at a leading antibody provider.
- Ranked number 299 on Deloitte’s Technology Fast 500™ and received several noteworthy recognitions for Quanterix’ Chief Executive Officer’s visionary leadership for healthcare disruption.
- Last month was added to the Nasdaq Biotechnology Index (NBI) as part of the annual re-ranking and attracted additional analyst coverage.
Was lead sponsor for
Powering Precision Health(PPH) annual summit held for the first time in Amsterdam, now an independent, nonprofit entity.
“We are proud of these achievements as they help demonstrate the power
of our technology and the disruptive innovation
To access the live webcast of Quanterix’ presentation at the 37th Annual
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release are based on Quanterix’ expectations and assumptions as of
the date of this press release. Each of these forward-looking statements
involves risks and uncertainties. Factors that may cause Quanterix’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed
in Quanterix’ filings with the